Equities

Century Therapeutics Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
IPSC:NSQ

Century Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.5808
  • Today's Change0.001 / 0.10%
  • Shares traded639.69k
  • 1 Year change-78.17%
  • Beta1.7914
Data delayed at least 15 minutes, as of Jul 18 2025 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Century Therapeutics, Inc. is a biotechnology company. The Company is focused on developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies and autoimmune diseases. The Company has created allogeneic cell therapy platform that includes induced pluripotent stem cells (iPSCs), differentiation know-how to generate immune effector cells from iPSCs, or iPSC- derived cells, clustered regularly interspaced short palindromic repeats, to incorporate multiple transgenes and remove target genes. The Company’s product candidates include CNTY-101, CNTY-308, CNTY-341, CNTY-107, and CNTY-104. Its lead product candidate CNTY-101 is a CAR-iNK cell therapy with six precision gene edits in a Phase I clinical trial for patients with B-cell mediated autoimmune diseases. CNTY-308 is a CD19-targeted, iPSC derived CAR T cell therapy. CNTY-341 is a dual-targeted CD19 and CD22 iPSC-derived CAR-T cell therapy.

  • Revenue in USD (TTM)114.90m
  • Net income in USD-21.95m
  • Incorporated2018
  • Employees140.00
  • Location
    Century Therapeutics Inc25 N 38TH STREET, 11TH FLOORPHILADELPHIA 19104United StatesUSA
  • Phone+1 (215) 981-4000
  • Fax+1 (302) 655-5049
  • Websitehttps://www.centurytx.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Grace Therapeutics, Inc0.00-9.57m46.33m32.00--0.6899-----0.8529-0.85290.004.860.00-------13.17-24.13-13.51-25.07-------48,136.22----0.00------25.56------
Clearside Biomedical Inc3.76m-30.81m46.77m32.00------12.42-0.4077-0.40770.0498-0.59410.1259--4.89117,625.00-103.03-67.79-126.15-84.9489.45---818.57-241.58---------79.77-5.20-5.75--108.16--
OS Therapies Inc0.00-13.27m47.20m4.00---------0.7949-0.79490.000.02880.00----0.00-426.54-----------------9.140.00-------37.51------
Neurosense Therapeutics Ltd0.00-10.21m47.26m15.00--17.72-----0.5489-0.54890.000.11120.00----0.00-263.14-145.64-884.37-198.79-----------230.280.00-------1.02---15.59--
P3 Health Partners Inc1.49bn-137.63m47.73m360.00--0.3426--0.0321-43.05-43.05475.7819.381.81--10.884,125,533.00-37.20-49.89-121.41-253.77-4.32-1.15-20.54-46.73---11.770.5868--18.4859.38-135.14------
Gain Therapeutics Inc0.00-20.93m48.41m23.00--8.01-----0.8868-0.88680.000.20110.00----0.00-159.74-79.58-258.86-95.32-------19,975.78----0.0689---100.00--8.34--10.39--
Exicure Inc0.00-5.86m48.71m8.00--4.28-----3.19-3.190.001.800.00----0.00-37.35-44.45-47.20-60.08-------259.52----0.00-----17.3442.65------
Century Therapeutics Inc114.90m-21.95m49.99m140.00--0.2079--0.4351-0.2819-0.28191.362.790.346----820,707.10-6.61-33.69-6.93-36.94-----19.10-3,876.28----0.00--194.81--7.40---42.55--
Actinium Pharmaceuticals Inc0.00-45.51m50.54m37.00--1.97-----1.47-1.470.000.82360.00----0.00-57.98-43.20-64.18-47.84-------7,408.74----0.0007---100.00--21.66---29.66--
Jasper Therapeutics Inc0.00-78.78m50.62m64.00--1.20-----5.25-5.250.002.810.00----0.00-85.84-75.11-97.08-86.11------------0.00-------10.55------
Precision BioSciences Inc51.14m-21.99m51.45m107.00--0.9921--1.01-2.01-2.016.474.680.3309--58.35473,527.80-14.22-26.22-16.69-33.68-----42.99-87.80----0.3117--40.9825.30116.85---59.31--
vTv Therapeutics Inc17.00k-18.69m51.62m23.00--6.51--3,036.72-3.01-3.010.00272.480.0004----739.13-53.13-96.30-68.57-------134,723.50-775.06----0.00-----18.128.83------
NRX Pharmaceuticals Inc0.00-24.11m52.39m2.00---------1.98-1.980.00-1.470.00-------423.80-210.73---603.16--------------------16.69------
Senti Biosciences Inc0.00-54.79m52.42m34.00--1.38-----10.30-10.300.001.460.00----0.00-59.25-50.97-66.56-57.59-------2,565.78----0.00---100.00--36.71---58.03--
Serina Therapeutics Inc65.00k-939.00k52.93m12.00--31.00--814.26-0.0516-0.05160.00680.17130.0074----5,416.67-11.53-188.54-153.87-------1,560.00-7,513.03----0.00---60.56-49.6424.74---49.05--
Data as of Jul 18 2025. Currency figures normalised to Century Therapeutics Inc's reporting currency: US Dollar USD

Institutional shareholders

20.83%Per cent of shares held by top holders
HolderShares% Held
Casdin Capital LLCas of 31 Mar 20253.21m3.78%
BlackRock Fund Advisorsas of 31 Mar 20252.74m3.22%
Fidelity Management & Research Co. LLCas of 31 Mar 20252.59m3.05%
The Vanguard Group, Inc.as of 31 Mar 20252.35m2.76%
DAFNA Capital Management LLCas of 31 Mar 20251.70m2.00%
Syncona Investment Management Ltd.as of 31 Mar 20251.21m1.43%
Renaissance Technologies LLCas of 31 Mar 20251.19m1.39%
Geode Capital Management LLCas of 31 Mar 2025970.26k1.14%
Tang Capital Management LLCas of 31 Mar 2025900.00k1.06%
SSgA Funds Management, Inc.as of 31 Mar 2025846.22k1.00%
More ▼
Data from 31 Mar 2025 - 31 Mar 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.